new data submitted of a 2nd assay shows enhanced potency compared to prochymal. hopefully this reassures fda the study was adequate and controlled. meeting next month.
"very encouraging" meeting re hfref. nothing else said apart from waiting on minutes.
anticipate further reduction in spend and funded to complete enrollment in back and adult gvhd.
Ann: Mesoblast 2024 Half Year Financial Results Webcast, page-53
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.060(4.11%) |
Mkt cap ! $1.724B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.54 | $1.45 | $4.868M | 3.253M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 28273 | $1.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.53 | 108302 | 6 |
View Market Depth
| Last trade - 13.58pm 12/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |